meperidine has been researched along with Vascular Diseases in 6 studies
Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.
pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.
Vascular Diseases: Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The gene for sickle cell disease is carried by 8% of the African-American population in the United States." | 1.28 | Sickle cell vaso-occlusive pain crisis in adults: alternative strategies for management in the emergency department. ( Pollack, CV; Sanders, DY; Severance, HW, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (66.67) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Manning, GW | 1 |
| Caudwell, GC | 1 |
| Koska, AJ | 1 |
| Kramer, WG | 1 |
| Romagnoli, A | 1 |
| Keats, AS | 1 |
| Sabawala, PB | 1 |
| Perlin, E | 1 |
| Finke, H | 1 |
| Castro, O | 1 |
| Rana, S | 1 |
| Pittman, J | 1 |
| Burt, R | 1 |
| Ruff, C | 1 |
| McHugh, D | 1 |
| Sanders, DY | 1 |
| Severance, HW | 1 |
| Pollack, CV | 1 |
| Roelofs, RI | 1 |
| Engel, WK | 1 |
| Frowein, RA | 1 |
| Karimi-Nejad, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Nitric Oxide for Inhalation in the Acute Treatment of Sickle Cell Pain Crisis[NCT00094887] | Phase 2 | 150 participants (Actual) | Interventional | 2004-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of hospitalization is defined as the length of time from admission to discharge order (NCT00094887)
Timeframe: within 40 days
| Intervention | Days (Median) |
|---|---|
| Inhaled Nitric Oxide | 4.06 |
| Placebo | 3.11 |
(NCT00094887)
Timeframe: within 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Nitric Oxide | 5 |
| Placebo | 7 |
Number of participants who required a blood transfusion before discharge because of acute chest syndrome/pneumonia (NCT00094887)
Timeframe: within 40 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Inhaled Nitric Oxide | 8 |
| Placebo | 7 |
"VOC resolution was defined by all of the following conditions:~Pain relief - Visual Analog Scale (VAS) pain scores of 6 or less, (6 as worst and 0 as best)~Freedom from parenteral narcotic use,~Ability to walk unless the subject was not able to walk for any reason other than acute VOC prior to the onset of crisis,~Subject and/or family's belief that the painful crisis could be managed at home with or without oral analgesic use, and the physician concurred with that assessment." (NCT00094887)
Timeframe: within 30 days
| Intervention | Hours (Median) |
|---|---|
| Inhaled Nitric Oxide | 61.83 |
| Placebo | 55.16 |
The number of participants readmitted to the hospital for any reason within 30 days after discharge (NCT00094887)
Timeframe: during first 24 hours and during 30 day follow-up
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| during first 24 hours | during 30-day follow-up | |
| Inhaled Nitric Oxide | 0 | 9 |
| Placebo | 0 | 17 |
The total dose (mg) of opioid medications received during the trial (NCT00094887)
Timeframe: within 8 hours and within 40 days
| Intervention | mg (Median) | |
|---|---|---|
| within 8 hours | within 40 days | |
| Inhaled Nitric Oxide | 16.25 | 153.75 |
| Placebo | 17.25 | 211.37 |
1 trial available for meperidine and Vascular Diseases
| Article | Year |
|---|---|
Enhancement of pain control with ketorolac tromethamine in patients with sickle cell vaso-occlusive crisis.
Topics: Adult; Analgesics; Anemia, Sickle Cell; Constriction, Pathologic; Digestive System Diseases; Double- | 1994 |
5 other studies available for meperidine and Vascular Diseases
| Article | Year |
|---|---|
THE EFFECT OF DEMEROL, ERGOTAMINE, AND DIHYDRO-ERGOTAMINE ON MORTALITY AFTER CORONARY OCCLUSION IN DOGS.
Topics: Animals; Coronary Occlusion; Coronary Vessels; Dogs; Ergotamine; Heart; Humans; Meperidine; Vascular | 1947 |
Pharmacokinetics of high-dose meperidine in surgical patients.
Topics: Aged; Chromatography, Gas; Constriction; Female; Humans; Injections, Intravenous; Liver; Male; Meper | 1981 |
Sickle cell vaso-occlusive pain crisis in adults: alternative strategies for management in the emergency department.
Topics: Acetaminophen; Adolescent; Adult; Amitriptyline; Analgesics; Anemia, Sickle Cell; Anti-Inflammatory | 1992 |
Myopathies associated with systemic diseases.
Topics: Alcoholism; Anti-Bacterial Agents; Chloroquine; Collagen Diseases; Endocrine System Diseases; Erythe | 1971 |
[Intensive therapy in craniocerebral injuries].
Topics: Adolescent; Adult; Aged; Brain Injuries; Child; Child, Preschool; Craniocerebral Trauma; Diazepam; H | 1969 |